BARDA releases five year strategic plan

The U.S. Biomedical Advanced Research Development Authority recently released a five year strategic plan that foresees many new projects ready for regulatory review in the next several years.

The agency’s director, Dr. Robin A. Robinson, recently said that the agency now has a robust product pipeline for nearly all threats, according to CIDRAP News.

"Many of these products in the development pipeline will become mature enough for acquisition and regulatory review over the next five years," Robinson said, CIDRAP News reports.

BARDA, the federal agency tasked with developing new countermeasures against bioterrorist attacks and emerging diseases, is part of the Department of Health and Human Services.

The new strategic plan was based in a large part on the goals and recommendations of a major HHS review on the nation’s biodefense efforts that was released in August 2010. The HHS review was prompted by delays in the production of the 2009 H1N1 pandemic flu vaccine, which was not readily available until after cases of the disease peaked in fall 2009.

The plan offers little in terms of specifics about new products, but instead focuses on broad goals related to the agency’s strategic plans, including the development of MCM’s for specific populations, expansion of a broad-spectrum antimicrobial program and investment in immune modulators, anti-inflammatories and immunity regulators.

BARDA was established in 2007 with the purpose of promoting the acquisition and development of medical defenses against chemical, biological, radiological and nuclear threats, as well as pandemic flu and emerging infectious diseases. The new strategic plan replaces the original, which was issued in 2007.